Biofrontera has launched a buyout on Roth Capital, share soars by Investing.com

By Sam Boughedda

Investing.com – Biopharmaceutical company Biofrontera Inc (NASDAQ 🙂 saw its stock price jump 135% to $ 6.19 on Wednesday after Roth Capital analysts launched the stock with a buy rating.

The stock, which debuted on October 28, has been steadily declining since it hit an intraday high of $ 4.99 in early November.

Roth analyst Jonathan Aschoff has set a 12-month price target of $ 20 for stocks, saying they project future US earnings from Ameluz and Xepi treatments in actinic keratosis and impetigo, respectively.

“Our initial assessment rules out the potential commercial uptick of any potential future program, given that BFRI is clearly focused on its two currently approved drugs,” Aschoff said.

On Tuesday, Biofrontera announced that it will release its third quarter results on November 30.

Disclaimer: Fusion media would like to remind you that the data contained in this site is not necessarily real time or accurate. All CFDs (stocks, indices, futures) and Forex prices are not provided by the exchanges but rather by market makers. The prices may therefore not be exact and differ from the actual market price, which means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media assumes no responsibility for any business losses that you may incur as a result of the use of such data.

Fusion media or anyone involved with Fusion Media will not accept any responsibility for any loss or damage resulting from reliance on any information, including data, quotes, graphics and buy / sell signals contained in this website. Please be fully informed about the risks and costs associated with trading in the financial markets, it is one of the riskiest forms of investing possible.